Search

Displaying results 4371 - 4380 of 10000 in total
  1. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … BCG versions due to the lack of the RD2 genome segment.

  2. Drug

    Ferric chloride

    go.drugbank.com/drugs/DB15536
    Approved

    Mixtures: ADDAMEL N 20 AMPUL, Addamel N
  3. Drug

    Palovarotene

    go.drugbank.com/drugs/DB05467
    Approved

    Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. … [A244920] Palovarotene was approved for use in Canada in January 2022 for the management of heterotopic ossification (HO) in patients with FOP, representing the first global approval for any FOP therapy

  4. Drug

    Inavolisib

    go.drugbank.com/drugs/DB15275
    ApprovedInvestigational

    Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers. … [L51748,L51738] In February 2025, it was approved by Health Canada for the same indication. [L52605]

    Synonyms: (2S)-2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)propanamide, propanamide, 2-((2-((4S)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-D)(1,4)benzoxazepin-9-yl)amino)-, (2S)-
  5. Drug

    Bumadizone

    go.drugbank.com/drugs/DB13286
    Approved

    Its use is restricted to these conditions, due to risks this drug poses [L5650]. … Bumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis

  6. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0247126
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  7. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0248893
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  8. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0248906
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  9. Pathway

    Cardiolipin Biosynthesis CL(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0249103
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  10. Pathway

    Cardiolipin Biosynthesis CL(20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)/20:5(5Z,8Z,11Z,14Z,17Z))

    smpdb.ca/view/SMP0250251
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate